LINCOLN

Lincoln Pharmaceuticals Share Price

 

 

Invest in Lincoln Pharmaceuticals with 3.06X leverage

Invest with MTF

Performance

  • Low
  • ₹493
  • High
  • ₹500
  • 52 Week Low
  • ₹490
  • 52 Week High
  • ₹980
  • Open Price₹500
  • Previous Close₹495
  • Volume8,104

Investment Returns

  • Over 1 Month -5.73%
  • Over 3 Month -11.73%
  • Over 6 Month -13.52%
  • Over 1 Year -46.36%

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.3
  • PEG Ratio
  • -0.7
  • Market Cap Cr
  • 988
  • P/B Ratio
  • Average True Range
  • 12.02
  • EPS
  • 39.94
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -5.22
  • RSI
  • 30.48
  • MFI
  • 8.65

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹493.15
-1.95 (-0.39%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹514.02
  • 50 Day
  • ₹524.60
  • 100 Day
  • ₹537.95
  • 200 Day
  • ₹563.43

Resistance and Support

495.22 Pivot Speed
  • R3 503.93
  • R2 501.72
  • R1 497.43
  • S1 490.93
  • S2 488.72
  • S3 484.43

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 632.17 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 28 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-13 Quarterly Results
2024-11-14 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.1.80 per share(18%)Final Dividend
View Lincoln Pharmaceuticals Dividend History Arrow

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
4.73%
36.26%
9.23%

About Lincoln Pharmaceuticals

  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹493 As on 07 December, 2025 | 22:03

The Market Cap of Lincoln Pharmaceuticals is ₹987.8 Cr As on 07 December, 2025 | 22:03

The P/E ratio of Lincoln Pharmaceuticals is 12.3 As on 07 December, 2025 | 22:03

The PB ratio of Lincoln Pharmaceuticals is 1.5 As on 07 December, 2025 | 22:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23